Additionally, we compared the in vivo efficacy of antibodies D and A to assess whether the differential activity observed on human Alzheimer’s disease seeds in vitro translates in vivo. Specific mouse models were chosen to evaluate the ability of these therapeutic tools to block the seeding or the propagation of pathological tau species. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.